Drug intelligence / Profile preview

cannabinoid oils

Development stage
Phase 3
Lead developer
Ethicann Pharmaceuticals
Modality
Small Molecules
Administration
Oral, Sublingual, Buccal, Inhalation
01

Overview

Cannabinoid oils are **pharmaceutical-grade, botanically sourced cannabinoid oil formulations containing tetrahydrocannabinol and cannabidiol** being developed by Ethicann Pharmaceuticals. Based on the provided context, this is a plant-derived cannabinoid combination product rather than a synthetic small molecule, intended for neurologic and pain indications including **multiple sclerosis-related spasticity, adult focal epilepsy, and cancer pain**. Its pharmacology is expected to derive primarily from mixed cannabinoid receptor modulation by THC together with the broader anticonvulsant and neuromodulatory effects of CBD, although the exact product composition, ratio, dosage form, and administration details were not specified in the source excerpt.

Other names
cannabinoid oilsTHC + CBD cannabinoid oilspharmaceutical-grade botanically sourced cannabinoid oils
02

Targets

CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on cannabinoid oils.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabinoid oils.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call